HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by GROUNDS, M. D. Articles by TORRISI, J. Search for Related Content PubMed PubMed Citation Articles by GROUNDS, M. D. Articles by TORRISI, J.

Anti-TNF (Remicade®) therapy protects dystrophic skeletal muscle from necrosis

School of Anatomy and Human Biology, The University of Western Australia, Western Australia, Australia 6009

¹Correspondence: School of Anatomy and Human Biology, The University of Western Australia, 35 Stirling Hwy., Crawley, Western Australia, Australia 6009. E-mail: mgrounds{at}anhb.uwa.edu

Necrosis of skeletal muscle fibers in the lethal childhood myopathy Duchenne muscular dystrophy (DMD) results from defects in the cell membrane-associated protein, dystrophin. This study tests the novel hypothesis that the initial sarcolemmal breakdown resulting from dystrophin deficiency is exacerbated by inflammatory cells and that cytokines, specifically tumor necrosis factor- (TNF), contribute to muscle necrosis. To block in vivo TNF bioactivity, young dystrophic mdx mice (a model for DMD) were injected weekly from 7 days of age with the anti-TNF antibody Remicade® before the onset of muscle necrosis and dystropathology that normally occurs at 21 days postnatally. The extent of inflammation, muscle necrosis, and myotube formation was measured by histological analysis from 18 to 28 days and muscle damage was also visualized by penetration of Evans blue dye into myofibers. Data from Remicade®-treated and control mdx mice were compared with mdx/TNF(–/–) mice that lack TNF. Pharmacological blockade of TNF activity with Remicade® clearly delayed and greatly reduced the breakdown of dystrophic muscle, in marked contrast to the situation in mdx and mdx/TNF(–/–) mice. Remicade® had no adverse effect on new muscle formation. Remicade® is a highly specific anti-inflammatory intervention, and clinical application to muscular dystrophies is suggested by this marked protective effect against skeletal muscle breakdown.—Grounds, M. D., Torrisi, J. Anti-TNF (Remicade®) therapy protects dystrophic skeletal muscle from necrosis.

Key Words: mdx mice • dystropathology • DMD

This article has been cited by other articles:

				N. P. Whitehead, C. Pham, O. L. Gervasio, and D. G. Allen N-Acetylcysteine ameliorates skeletal muscle pathophysiology in mdx mice J. Physiol., April 1, 2008; 586(7): 2003 - 2014. [Abstract] [Full Text] [PDF]

				M. Suelves, B. Vidal, A. L. Serrano, M. Tjwa, J. Roma, R. Lopez-Alemany, A. Luttun, M. M. de Lagran, M. A. Diaz, M. Jardi, et al. uPA deficiency exacerbates muscular dystrophy in MDX mice J. Cell Biol., September 7, 2007; 178(6): 1039 - 1051. [Abstract] [Full Text] [PDF]

				M. Schwarzkopf, D. Coletti, D. Sassoon, and G. Marazzi Muscle cachexia is regulated by a p53-PW1/Peg3-dependent pathway Genes & Dev., December 15, 2006; 20(24): 3440 - 3452. [Abstract] [Full Text] [PDF]

				S. Messina, D. Altavilla, M. Aguennouz, P. Seminara, L. Minutoli, M. C. Monici, A. Bitto, A. Mazzeo, H. Marini, F. Squadrito, et al. Lipid Peroxidation Inhibition Blunts Nuclear Factor-{kappa}B Activation, Reduces Skeletal Muscle Degeneration, and Enhances Muscle Function in mdx Mice Am. J. Pathol., March 1, 2006; 168(3): 918 - 926. [Abstract] [Full Text] [PDF]

				M. A. Spruit, R. Gosselink, T. Troosters, A. Kasran, M. Van Vliet, and M. Decramer Low-Grade Systemic Inflammation and the Response to Exercise Training in Patients With Advanced COPD Chest, November 1, 2005; 128(5): 3183 - 3190. [Abstract] [Full Text] [PDF]

				Y. -W. Chen, K. Nagaraju, M. Bakay, O. McIntyre, R. Rawat, R. Shi, and E. P. Hoffman Early onset of inflammation and later involvement of TGF{beta} in Duchenne muscular dystrophy Neurology, September 27, 2005; 65(6): 826 - 834. [Abstract] [Full Text] [PDF]

				B. W. Tobin and P. N. Uchakin Nutritional Consequences of Critical Illness Myopathies J. Nutr., July 1, 2005; 135(7): 1803S - 1805S. [Full Text] [PDF]

				A. Anandacoomarasamy, G. Howe, and N. Manolios Advanced refractory polymyositis responding to infliximab Rheumatology, April 1, 2005; 44(4): 562 - 563. [Full Text] [PDF]

				A. De Luca, B. Nico, A. Liantonio, M. P. Didonna, B. Fraysse, S. Pierno, R. Burdi, D. Mangieri, J.-F. Rolland, C. Camerino, et al. A Multidisciplinary Evaluation of the Effectiveness of Cyclosporine A in Dystrophic Mdx Mice Am. J. Pathol., February 1, 2005; 166(2): 477 - 489. [Abstract] [Full Text] [PDF]

				F. X Pizza, J. M Peterson, J. H Baas, and T. J Koh Neutrophils contribute to muscle injury and impair its resolution after lengthening contractions in mice J. Physiol., February 1, 2005; 562(3): 899 - 913. [Abstract] [Full Text] [PDF]